Cargando…

Efficacy of subcutaneous tocilizumab in patients with rheumatoid arthritis and systemic sclerosis overlap syndrome: a report of two cases and review of the literature

BACKGROUND: The details of two rheumatoid arthritis (RA) patients with systemic sclerosis (SSc) who were administered tocilizumab, an anti-interleukin-6 receptor antibody, are reported, along with a review of the literature. CASE PRESENTATION: Two RA patients with SSc with inadequate responses to di...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wakabayashi, Hiroki, Kino, Hitoshi, Kondo, Makoto, Yamanaka, Keiichi, Hasegawa, Masahiro, Sudo, Akihiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6480678/ https://www.ncbi.nlm.nih.gov/pubmed/31049490 http://dx.doi.org/10.1186/s41927-019-0063-x

Ejemplares similares

Efficacy of Switching from Infliximab to Subcutaneous Golimumab in Patients with Rheumatoid Arthritis to Control Disease Activity or Adverse Events
por: Wakabayashi, Hiroki, et al.
Publicado: (2016)

The Onset of Subtalar Joint Monoarthritis in a Patient with Rheumatoid Arthritis
por: Wakabayashi, Hiroki, et al.
Publicado: (2022)

Refining the Management of Rheumatoid Arthritis: the Benefits of Subcutaneous Tocilizumab
por: Negoescu, Andra F., et al.
Publicado: (2014)

A Case of Rheumatoid Arthritis and Limited Systemic Sclerosis Overlap Successfully Treated with Tocilizumab for Arthritis and Concomitant Generalized Lymphadenopathy and Primary Biliary Cirrhosis
por: Saito, Eiko, et al.
Publicado: (2014)

Sustainable Efficacy of Switching From Intravenous to Subcutaneous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis
por: Ogata, Atsushi, et al.
Publicado: (2015)

Tenascin-C in Osteoarthritis and Rheumatoid Arthritis
por: Hasegawa, Masahiro, et al.
Publicado: (2020)

Long-Term Maintenance of Golimumab Effectiveness for Injection Spacing in Rheumatoid Arthritis Patients with Low Disease Activity Who Previously Received Other TNF Inhibitors: Minimum 2-year Data From an Observational Study
por: Wakabayashi, Hiroki, et al.
Publicado: (2021)

Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2019)

Drug delivery options to increase patient adherence and satisfaction in the management of rheumatoid arthritis – focus on subcutaneous tocilizumab
por: Nakashima, Yasuharu, et al.
Publicado: (2014)

Phase III Study of the Efficacy and Safety of Subcutaneous Versus Intravenous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis
por: Ogata, Atsushi, et al.
Publicado: (2014)

Accelerated subcutaneous nodulosis in patients with rheumatoid arthritis treated with tocilizumab: a case series
por: Talotta, Rossella, et al.
Publicado: (2018)

Tocilizumab Induced Acquired Factor XIII Deficiency in Patients with Rheumatoid Arthritis
por: Mokuda, Sho, et al.
Publicado: (2013)

Subcutaneous Tocilizumab Versus Placebo in Combination With Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis
por: Kivitz, Alan, et al.
Publicado: (2014)

Subcutaneous Aspergillus nodule with cutaneous Enterococcus infection
por: Kondo, Makoto, et al.
Publicado: (2021)

Review of tocilizumab in the treatment of rheumatoid arthritis
por: Okuda, Yasuaki
Publicado: (2008)

Tocilizumab in the treatment of rheumatoid arthritis and beyond
por: Shetty, Anjali, et al.
Publicado: (2014)

Tocilizumab: A Review in Rheumatoid Arthritis
por: Scott, Lesley J.
Publicado: (2017)

Potential patient benefit of a subcutaneous formulation of tocilizumab for the treatment of rheumatoid arthritis: a critical review
por: Besada, Emilio
Publicado: (2014)

Impact of tocilizumab administered intravenously or subcutaneously on patient-reported quality-of-life outcomes in patients with rheumatoid arthritis
por: Strand, Vibeke, et al.
Publicado: (2018)

Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis
por: Choy, Ernest, et al.
Publicado: (2019)

A case of bone necrosis with pseudotumor following metal-on-metal total hip arthroplasty
por: Hasegawa, Masahiro, et al.
Publicado: (2017)

Tocilizumab Effectiveness After Switching from Intravenous to Subcutaneous Route in Patients with Rheumatoid Arthritis: The RoSwitch Study
por: Darloy, Jean, et al.
Publicado: (2019)

Safety and Efficacy of Tocilizumab for the Treatment of Rheumatoid Arthritis
por: Ogata, Atsushi, et al.
Publicado: (2012)

Longitudinal immunomonitoring following Tocilizumab in rheumatoid arthritis
por: Pers, Yves-Marie, et al.
Publicado: (2011)

Tocilizumab Attenuates Anti-neutrophil Cytoplasmic Antibody-associated Nephritis Occurring during Abatacept and Adalimumab Therapy for Rheumatoid Arthritis
por: Yoshimura, Yusuke, et al.
Publicado: (2022)

Case of Scedosporium aurantiacum infection detected in a subcutaneous abscess
por: Kondo, Makoto, et al.
Publicado: (2018)

Tocilizumab treatment safety in rheumatoid arthritis in a patient with multiple sclerosis: a case report
por: Sato, Hiroe, et al.
Publicado: (2014)

Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients
por: Koike, Takao, et al.
Publicado: (2011)

A 16-year Follow-up Case of Interstitial Pneumonia with Systemic Sclerosis-rheumatoid Arthritis Overlap Syndrome
por: Yamakawa, Hideaki, et al.
Publicado: (2017)

Pharmacokinetic and Pharmacodynamic Analysis of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis From 2 Randomized, Controlled Trials: SUMMACTA and BREVACTA
por: Abdallah, Hisham, et al.
Publicado: (2016)

Predictive Factors for Rheumatoid Arthritis Flare After Switching From Intravenous to Subcutaneous Formulation of Tocilizumab in Real-World Practice
por: Ahn, Soo Min, et al.
Publicado: (2022)

Subcutaneous Sarilumab in Patients With Rheumatoid Arthritis who Previously Received Subcutaneous Sarilumab or Intravenous Tocilizumab: An Open‐Label Extension of a Randomized Clinical Trial
por: Emery, Paul, et al.
Publicado: (2020)

Serum level of oxidative stress marker is dramatically low in patients with rheumatoid arthritis treated with tocilizumab
por: Hirao, Makoto, et al.
Publicado: (2011)

Hepatotoxicity of tocilizumab and anakinra in rheumatoid arthritis: management decisions
por: Mahamid, Mahmud, et al.
Publicado: (2011)

Early intervention in the treatment of rheumatoid arthritis: focus on tocilizumab
por: Yilmaz, Sedat, et al.
Publicado: (2013)

Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab
por: Rubbert-Roth, Andrea, et al.
Publicado: (2016)

Tocilizumab-Induced Dermatosis in a Patient With Rheumatoid Arthritis
por: Babkoor, Doaa, et al.
Publicado: (2022)

Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries
por: Choy, Ernest, et al.
Publicado: (2018)

Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries
por: Choy, Ernest, et al.
Publicado: (2018)

Efficacy and safety of subcutaneous tocilizumab in rheumatoid arthritis over 1 year: a UK real-world, open-label study
por: Isaacs, John D, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_uvhr6sb869dm1ou1pihii1gs0h